TNFR2-Fc-IL-1raAlternative Names: TFI - Hangzhou Anruipu Biological Technology
Latest Information Update: 14 Apr 2016
At a glance
- Originator Hangzhou Anruipu Biological Technology
- Class Interleukins; Recombinant fusion proteins; Tumour necrosis factors
- Mechanism of Action Interleukin 1 receptor antagonists; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 14 Apr 2016 No recent reports on development identified - Preclinical for Inflammation in China (unspecified route)